25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
Name:
s41416-018-0179-6.pdf
Size:
373.1Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
Lipplaa, AFernandes, R
Marshall, A
Lorigan, Paul C
Dunn, J
Myers, K
Barker, E
Newton-Bishop, J
Middleton, M
Corrie, P
Affiliation
Department of Oncology, University of Oxford, CB2 0QQ, OxfordIssue Date
2018-07-23
Metadata
Show full item recordAbstract
Studies evaluating a relationship of vitamin D in patients with primary melanoma have consistently identified an inverse correlation with Breslow thickness, but an inconsistent impact on survival. Vitamin D in later stages of melanoma has been less studied.Citation
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. 2018, Br J CancerJournal
British Journal of CancerDOI
10.1038/s41416-018-0179-6PubMed ID
30033445Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/s41416-018-0179-6